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Assessment of the cellular origin of allograft valves is essential in comprehending their biologic 
behavior and in improving preparation methods. In this study we retrospectively analyzed 10 
allografts obtained from patients who underwent valve replacement or heart transplantation. 
Histologic evaluation and deoxyribonucleic acid amplification by polymerase chain reaction tech- 
nology with fluorescence labeled primers was performed on different parts of the valve leaflets. 
Automated analyses of the obtained amplimers showed in the heart transplantation group the 
presence of receptor ceils interspersed with native donor cells in three cases. Preliminary results for 
the valve replacement group are inconclusive as yet. (J THORAC CARDIOVASC SURG 1995;109:218-23) 
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Al logra f t  valve replacement is considered in two 
different clinical situations: valve replacement and 
heart transplantation. In the valve replacement 
group, the valves are usually cryopreserved and the 
recipients are not immunosuppressed. The late re- 
sults of these substitutes are good, with acceptable 
valve gradients and a low incidence of thromboem- 
bolism and endocarditis. However, the durability of 
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cryopreserved allografts is limited and the failure 
rate increases with time.*' 2 In the heart transplan- 
tation group the valves are fresh and viable, and 
their recipients are immunosuppressed. During a 
period of up to 6 years these valves functioned 
normally and there were no cases of endocarditis or 
thromboembolism. Histologic studies were made to 
determine the structure of the explanted leaflets. 
Pathologic specimens were assessed genetically to 
evaluate the origin of the cells from fragments of the 
valve leaflets. Polymerase chain reaction (PCR) 
technology 3 was used with ftuorochrome-labeled 
primers to amplify (CA)n hypervariable deoxyribo- 
nucleic acid (DNA) target regions 4'5 from very 
small amounts of DNA extracted from various por- 
tions of explanted aortic valve leaflets. 
Material and methods 
Ten valves were retrospectively analyzed from five 
patients who had undergone allograft valve replacement 
and from five who had had heart transplantation. All
valves from the valve replacement group were removed 
during reoperations and valves from the heart ransplan- 
tation group were collected uring postmortem examina- 
tion. These valves were obtained with approval from the 
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Table I. Donor and receiver information for allografl valve replacement and heart transplantation groups 
Age Sex Blood group 
Cold IT Cryo storage Follow-up 
Case D R D R D R (hr) (days) (too) 
A1 23 72 M M A-  A+ 36 54 2 
A2 21 62 M F A+ A+ 24 19 6 
A3 40 64 M M A+ A+ 24 33 2 
A4 30 45 M F NA A+ 48 14 12 
A5 42 23 M M A+ O+ 168 0 72 
T1 29 53 M M O-  O+ 2.0 1 
T2 28 53 M M A+ A+ 2.2 2 
T3 19 42 F M A-  A+ 2.8 5 
T4 25 60 F M A+ A+ 1.5 4 
T5 41 61 M M A+ A-  2.0 38 
A, Valve replacement group; T, heart ransplantation group; D, donor; R, receiver; IT, Ischemic time; NA, not available. 
national institutional review board. In the valve replace- 
ment group the donor valves were retrieved from brain 
dead donors (three cases) and from cadavers (two cases). 
In the heart transplantation group all the hearts were 
obtained from brain dead donors. After heart transplan- 
tation all patients were given cyclosporine, azathioprine, 
and prednisone for immunosuppression. Four patients 
incurred one to three treated rejection episodes. All 
patients in the heart transplantation group died with no 
evidence of rejection, except for patient T1, who died 1 
month after the operation with signs of mild rejection. 
The mean age, sex distribution, blood type, and valve 
information for the valve replacement and heart trans- 
plantation groups are outlined in Table I. 
One leaflet of each valve was used for genetic evalua- 
tion. The leaflet was divided into one to four fragments for 
the valve replacement group and into four to 21 fragments 
in the heart ransplantation group depending on the size 
and quality of the sample. Blood samples or small portions 
of native aortic tissue were collected as a source of 
constitutional DNA for comparative studies. From solid 
tissue, DNA was obtained by the standard proteinase 
K method followed by phenol-chloroform extraction, 
whereas the guanidine-hydrogen chloride method was 
used for blood. 6DNA was amplified by PCR technology 
by means of primers in which one primer is fluorescently 
labeled. Oligonucleotide primers flanking the hypervari- 
able (CA). repeat regions 7-10 were synthesized by a 381 
DNA synthesizer (Applied Biosystems, Inc., Foster City, 
Calif.). A fluorescent dye (5-carboxyfluorescein [FAM] or 
2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein [JOE]) 
was attached to the 5' end of the pair of PCR primers 
using Aminolink 2 (Applied Biosystems, Inc.) and were 
purified by high-performance liquid chromatography, as 
described by Gibbs and associates. 11The size of the 
(CA)n-containing amplimers i determined by referencing 
them to the internal ane size standards by means of 
the GENESCAN 672 software (Applied Biosystems, 
inc.).12, 13 
Results 
Histologic studies indicated that the valve leaflets 
from the valve replacement group lost their normal 
structure. There was evidence of hyallnization and 
predominant ground substance, sometimes with focal 
calcification. Small quantities of fibroblasts were found 
only in cases A1 and A2. Endothelial cells were not 
found in any of the cases and in three cases there was 
evidence of focal polymorphonuclear infiltration. In 
the heart transplantation group, histologic evaluation 
was almost normal with a slight decrease in the num- 
ber of cells at the free edge of the leaflets. The 
endothelium was focally maintained and none of the 
leaflets howed inflammatory infiltrations. 
The valve replacement group was genetically as- 
sessed with marker D5S82, which yielded a het- 
erozygous profile in two samples (A1 and A4) and 
homozygous profiles for the remaining three sam- 
ples. An electrophoretogram with more than two 
peaks was not encountered for any of the valve 
replacement cases, so that the results were incon- 
clusive. Sample A4 exhibited two different sized 
amplimers in the interior region of the leaflet and 
one amplimer with a very small area in the exterior 
region of the leaflet. DNA controls from the re- 
ceiver were obtained in cases A1 and A2, in which 
the same genotypes as those present in the valves 
were found. For the heart transplantation group, 
three different sized amplimers in three cases (T1, 
T3, and T5) were obtained. In two cases (T1 and T5) 
we found a very high difference in the area of one 
amplimer as compared with the other, demonstrat- 
ing the presence of one population with a homozy- 
gous profile and another with a heterozygous profile 
(Fig. 1). We were unable to find any of these types 
of electrophoretograms in case T2. Analysis of T4 
indicates a homozygous profile in the valve and a 
heterozygous profile for the control DNA (recipi- 
ent). Results for case T5, showing three different 
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Fig. 1. Electrophoretograms of PCR products with primers for D5S299, case T5 (top, fragment A; bottom, 
control) corresponding todata in Table II. The abscissa indates ize in base pairs and the ordinate indicates 
fluorescence intensity. 
sized amplimers using marker D5S299 and two 
different sized amplimers with areas differing by a 
factor of 2 using marker D5S346, are presented in 
Table II. 
Discussion 
The aim of this study is to determine allograft 
leaflet cellular origin with and without he influence 
of immunosuppression by means of a new method of 
fluorescent primers in PCR and electrophoresis. 
This type of automated DNA analysis using primers 
in a PCR reaction in which one of them is fluores- 
cently labeled enables us to accurately genotype and 
quantify the obtained amplimers. Cell origin (donor 
or recipient) was not always visually apparent, espe- 
cially when the control and valve DNA samples were 
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Table II. Genetic profiles for case T5 of the heart transplantation group for different sections of the leaflet 
indicating the obtained size in base pairs (bp) for each amplimer and their respective areas 
D5S299 D5S346 
Fragment Size Area Size Area Size Area Size Area Size Area 
A 158 498 178 516 184 535 114 5761 116 3101 
B 158 570 178 1917 184 1585 114 7207 116 2571 
D 158 2455 178 703 184 347 114 20192 116 9875 
Control 158 38555 114 35618 116 33092 
The receiver DNA is represented as the control. Fragment segment locations are labeled A through D, with A as the outermost segment and D as the 
innermost segment. 
*No DNA amplification. 
amplified to the same size in the PCR reaction. This 
verifies that quantified areas evaluated by the 
GENESCAN 672 software are crucial for assessing 
quantification. With respect o scoring accuracy, the 
electrophoretograms obtained show that homozy- 
gous genotypes can be readily distinguished from 
heterozygotes, which differ by only two nucleotides 
in the size of their alleles. 
The most striking factor for the valves in the valve 
replacement group was the marked decrease in 
cellularity. The presence of infection in a few of 
these valves made the DNA assessment of the native 
cells controversial because the obtained DNA am- 
plification may be due to infection-related leuko- 
cytes. So that this problem could be avoided, five 
slices of 5 /xm each from the same region as that 
used for genetic assessment were histologically ex- 
amined and found to contain no white blood cells. 
Results in the valve replacement group indicated a 
heterozygous profile in A1 and a homozygous pro- 
file in A2. The respective DNA controls had similar 
profiles indicating coincidental genotypes for recip- 
ient and donor in both cases or total inhabitation of 
the cells of the valves by host cells. For the heart 
transplantation group a pattern of three DNA pro- 
files was found in three cases, and within these a 
pattern of two DNA profiles was found by the use of 
different markers in which the area of one allele is 
notably different from the other. This enables us to 
deduce the genotype of the donor as homozygous 
for the more concentrated band. These findings 
were confirmed by the use of three different mark- 
ers, proving a double origin of these cells. In one 
case we encountered recipient cells within all frag- 
ments of the leaflet and a patchy distribution of 
endothelial cells. Morphologic studies showed that 
the number of endothelial cells was negligible as 
compared with the number of fibroblasts. There- 
fore, we conclude that the cells yielding DNA for 
amplification are the most abundant cells, the fibro- 
blasts. For case T5 with the marker D5S299, the 
amount of DNA-amplified product showed that the 
cell population at the free edge of the cusps was 
predominately from the recipient and the cells at the 
base were from mixed origins. These differences in 
location of cell population along the leaflet require 
further research before any conclusion can be 
reached. 
The overall method used in this study represents 
a promising alternative to conventional genetic 
screening. The combination of PCR with the sensi- 
tivity of the fluorescent PCR alternative and the use 
of specific software to screen and to quantify the 
obtained amplimers results in a time-saving method 
with enhanced sensitivity and accuracy of detection. 
Further use of new genetic assessment methods will 
definitely improve our knowledge of the cellular 
content of the allograft valve in heart transplants 
and valve replacement. 
We thank Dr. Eric Mayrand and Dr. Margaret Galvin 
form Applied Biosystems, Inc., Foster City, California, for 
their assistance in automated DNA analysis. 
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Discussion 
Dr. A. C. Yankah (Berlin, Germany). Dr. Melo, I agree 
with you that allografts are antigenic. The viable allografts 
and even the allovital grafts are subjected to immunologic 
attack and trauma. Consequently, the endothelial cells as 
well as the fibroblasts and the collagen structures would be 
destroyed after implantation after an immune response by 
the host. The immunologic omplications are our major 
concern, especially in children. Unless the immune re- 
sponse is delayed or arrested by means of a nontoxic dose 
of immunosuppression such as cyclosporine to inhibit 
T-lymphocyte activation and prevent structural deteriora- 
tion, the durability of the viable allograft valve would be 
limited. It has been demonstrated in our animal experi- 
mental aboratory that in rats a short course of cyclospo- 
fine therapy with a dose of 10 mg/kg for 14 days beginning 
from the day of operation can achieve unresponsiveness of 
the host to the allograft. Subsequently, the endothelial 
cells and the fibroblasts could be preserved. The cells 
could survive to replicate, the structures and valve integ- 
rity could be maintained, and therefore durability of the 
allograft could be prolonged. In certain rat strains (weakly 
allogeneic) with major histocompatibility-compatible, 
non-major histocompatibility-incompatible encoded en- 
dothelial cells, prolonged if not indefinite valve durability 
could be achieved after a short-course nontoxic dose of 
cyclosporine. 
If these findings are applicable in the clinical situation, 
then this implies that patients who are at risk for forming 
antibodies against allograft valves could benefit from a 
tissue typing especially for HLA-DR compatibility and an 
additional short-course nontoxic dose of immunosuppres- 
sive therapy for about 3 months. Observations made in 
heart transplant patients in whom aortic valve function 
was always normal during acute or chronic rejection 
support and justify the use of some type of immunosup- 
pression in high-risk patients who are electively scheduled 
to receive an allovital graft. 
The two slides confirm the results of the animal exper- 
iments we performed at the Institute of Immunology at 
the University of Kiel, Germany. Allografts in rats not 
treated with cyclosporine A lost their endothelial cells 
after a humoral rejection, leaving bare collagen structures 
in the blood circulation. Subsequently the fibroblasts died 
away and the valve became acellular. The lost endothe- 
lium, however, was replaced by a thin layer of fibrous 
neointima. Very interestingly, no thrombotic formations 
were observed on the vane surfaces. 
In the cyclosporine-treated rats the endothelial cells 
were maintained until postoperative day 250, when the 
experiment was terminated. The endothelial cells could be 
identified by factor VII and Ulex europaeus lectin identi- 
fication test, and endothelial cell origin was shown by 
means of donor and recipient specific monoclonal anti- 
bodies as well as monoclonal ntibodies (OX6) directed at 
major histocompatibility class II rat endothelial antigens. 
In the control syngeneic grafts or the isografts (herein 
referred to as autografts), no immune response was 
detected by direct immunofluorescence study. The iso- 
grafts were viable and durable at the completion of the 
experiment on day 250. 
I would like to address one question to Dr. Melo. Can 
you apply your method to identify the donor or recipient 
endothelial cells? 
Dr. Melo. This method is very useful. Of course, the key 
issue regarding this study concerns which cells we are 
looking at. Are they endothelial cells or fibroblasts? 
Evaluating the allograft group is easy because we could 
not show, in any of these specimens that were kept in 
pathology, any endothelial cells on the surface of these 
allografts. We were able to get PCR amplification, but 
because we had just one band, it could be either from the 
donor or from the recipient. However, this DNA defi- 
nitely did not come from the endothelial cells of the 
donor. 
The second issue concerns the transplantation group. 
The endothelial cells assessed by cytology are scarce, the 
main reason being that all these examinations have at 
least a 24-hour delay after death. At histologic examina- 
tion all the controls showed the endothelial cells to be 
present, but in a patchy distribution. In two of the three 
samples both donor and recipient ceils were present in all 
the pieces tudied, which would be impossible if the DNA 
were from the endothelial cells. This indicates that we are 
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looking at fibroblasts. Besides, this method is quantitative, 
which gives you an idea of the number of cells present. 
This is a second reason to believe that most DNA is from 
the fibroblasts. 
Mr. Magdi H. Yacoub (Harefield, England). Dr. Melo, I 
have two questions for you. What were the genetic 
markers used for the PCR? What was the exact sequence 
and what genes were you targeting and why? 
Second, what is the interval between insertion and 
examination i both types? 
Dr. Melo. Regarding your first question, I will have my 
genetics colleagues provide you all the information. I 
think they chose their markers because of the specificity of 
the Portuguese population. One of the characteristics of a 
small country like ours is that it is much more homozygous 
than a population in which there is a greater crossing of 
races. 
Regarding the second question, in patients having 
aortic valve replacement there is a very large delay 
between implantation and removal, which varied from 
2 months to 6 years. In the transplantation group the 
average time was 7 months. 
Dr. Yacoub. Did you evaluate the effect of time? 
Dr. Melo. Yes, and we could show exactly on these 
three allografts where we have seen donor and recipient 
cells; one allograft had 1 month, another 6 months, and 
the other 4 years after implantation. They were in the 
shortest, medium, and longest ime after transplantation. 
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